Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 10/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.42 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | RXRG | P48443 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30454075 | 1.00 | PTGER1 (0.47) | PTGER1CYP2C9CYP3A4PIN1MDM2 | |
| SCHEMBL24257668 | 0.89 | FFAR1 (0.43) | PTGER1PIN1MRGPRX4ADORA1 | |
| SCHEMBL30453291 | 0.87 | C5AR1 (0.43) | PTGER1MRGPRX4 | |
| SCHEMBL24257669 | 0.87 | C5AR1 (0.43) | PTGER1MRGPRX4 | |
| SCHEMBL24257539 | 0.86 | MCL1 (0.44) | PTGER1MRGPRX4 | |
| SCHEMBL30453121 | 0.86 | MAOB (0.47) | CYP2C9CYP3A4PIN1MRGPRX4ADORA1 | |
| SCHEMBL24257685 | 0.86 | MAOB (0.47) | CYP2C9CYP3A4PIN1MRGPRX4ADORA1 | |
| SCHEMBL24257835 | 0.84 | VEGFA (0.49) | ADORA1GPR119 | |
| SCHEMBL24257532 | 0.84 | CNR2 (0.48) | PTGER1CYP2C9CYP3A4ADORA1MAPK1 | |
| SCHEMBL30453143 | 0.84 | CNR2 (0.48) | PTGER1CYP2C9CYP3A4ADORA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-116670131-A | PHD inhibitor compounds, compositions, and methods of use | 阿克比治疗有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | PTGER1 206/4885CYP2C9 3954/4885CYP3A4 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.